Altisource Asset Management Corp (AAMC), Affimed Therapeutics BV (AFMD): Orbimed Advisors and Luxor Capital Group Are Bullish on These Companies

Altisource Asset Management Corp (NYSEMKT:AAMC) and Affimed Therapeutics BV (NASDAQ:AFMD) felt hedge funds’ bullishness lately. Samuel Isaly’s Orbimed Advisors recently started a new position, with 5.81 million shares, at Affimed Therapeutics BV (NASDAQ:AFMD), while Christian Leone’s Luxor Capital Group boosted its exposure to Altisource Asset Management Corp (NYSEMKT:AAMC), and now owns 429,976 shares.

Altisource Asset Management Corp (NYSEMKT:AAMC) is a $1.62 billion market cap asset management company that provides portfolio management and corporate governance services. A few days ago, Luxor Capital Group disclosed the purchase of 100 shares of the company’s Common Stock, for a price of $675 per share. These shares add to the 429,976 shares disclosed on September 12, which accounted for approximately 13.8% of the shares outstanding calculated in accordance with the Blocker restrictions.

This stake makes of Luxor the largest hedge fund shareholder (amongst those we keep track of) in Altisource Asset Management Corp (NYSEMKT:AAMC), trailed by Brian Jackelow’s Sab Capital Management, which last disclosed ownership of 219,298 shares, worth more than $158 million, by the end of the second quarter of the year.

Affimed Therapeutics BV (NASDAQ:AFMD) is a recently IPOed $147.1 million market cap clinical-stage biopharmaceutical company focused on discovering and developing targeted cancer immunotherapies. The company saw Samuel Isaly’s Orbimed Advisors start a new position, with 5.81 million shares, recently, as its previous holdings at Affimed Therapeutics AG (now a holly-owned subsidiary of Affimed Therapeutics B.V.) were converted to the new company’s Common Stock. The fund may be deemed to be the beneficial owner of approximately 24.02% of the company’s shares outstanding. The filing was accompanied by a Carve-Out Agreement that you can check out in detail here.

Affimed Therapeutics BV (NASDAQ:AFMD)’s initial public offering of 8,000,000 common shares at an initial public offering price of $7.00 per common share was closed on September 17. However, the company has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 common shares from Affimed at the public offering price.

Disclosure: Javier Hasse holds no positions in any stocks or funds mentioned